肿瘤类器官模型揭示胰腺癌放化疗的时序反应与交互作用
该研究基于逻辑斯谛生长常微分方程(ODE)构建数学预测框架,模拟化疗、放疗及放化疗对患者来源肿瘤类器官(PDTO)的杀伤效应。对3例PDTO样本进行4 Gy和8 Gy放疗、FOLFIRINOX化疗及联合方案处理,拟合平均NMSE均小于0.0045。模型揭示化疗早期显效、放疗第一周后期(约第4天)起效且放疗后约第8天出现显著二次反应,联合治疗中放疗杀伤可能占主导。
要点
- ODE模型可高精度拟合PDTO放化疗后的生长动态,平均NMSE小于0.0045。
- 化疗早期杀伤明显,放疗第一周约第4天起效,放疗后约第8天出现显著二次反应。
- 放化疗联合兼具两阶段效应,建模提示放疗杀伤在联合交互中可能占主导。
核心结论
- 基于ODE的数学预测框架能高精度建模PDTO对化疗、放疗和放化疗的异质性治疗反应。
- 模型揭示了化疗与放疗的动态杀伤效应及其交互作用,联合治疗中放疗杀伤可能占主导。
研究设计与样本
- 研究构建基于逻辑斯谛生长常微分方程(ODE)的数学预测框架,模拟化疗和放疗诱导的杀伤效应。
- 从不同患者培养PDTO,分别给予4 Gy和8 Gy放疗、FOLFIRINOX化疗(按预先确定的类器官特异性IC50剂量)及联合方案处理。
- 每例患者追踪测量20-40个类器官直径,用明场图像在每次治疗后长达7或9天捕获生长动态数据用于模型拟合。
- 以数据拟合的平均归一化均方误差(NMSE)评估建模准确性。
主要发现
- 所提数学建模框架准确捕获了3例PDTO样本在化疗、放疗和放化疗后的生长动态,拟合平均NMSE均接近零(小于0.0045)。
- 拟合参数(杀伤强度、效应窗口和峰值杀伤时间)定量揭示不同PDTO间治疗反应存在显著异质性。
- 化疗在早期阶段显示明显效果,放疗在第一周较晚阶段(约第4天)起效,放疗后约第8天出现显著更强的二次反应。
- 放化疗联合兼具两种模态的优势,在两个反应阶段均产生明显效应,建模结果提示放疗诱导的杀伤效应可能在联合交互中起主导作用。
临床怎么用
- 该PDTO建模框架可作为优化治疗方案和指导临床试验设计的工具,从而提升个体化医疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Model the therapeutic effects of chemotherapy, radiotherapy, and chemoradiotherapy to study the heterogeneous responses of patient-derived tumor organoids (PDTOs). METHODS: We proposed novel mathematical forecasting frameworks based on logistic growth ordinary differential equations (ODEs) and the characteristics of tumor responses to model the therapeutic effects of chemo- and radiation-induced killing. To validate the models, we cultured PDTOs from different patients and treated them with radiation (4 Gy and 8 Gy), chemotherapy (FOLFIRINOX at a previously determined organoid-specific IC50 dose), and combined regimens, respectively. The diameters of 20-40 organoids per patient were tracked and measured using brightfield images up to 7 or 9 days following each treatment to capture organoid growth dynamics data, which was used for model fitting. The accuracy of the modeling was evaluated by the average normalized mean squared errors (NMSE) of data fitting. RESULTS: The proposed mathematical modeling frameworks accurately captured the observed growth dynamics of three PDTO samples after chemotherapy, radiotherapy, and chemoradiotherapy, as reflected by the average NMSE of data fitting, which are all close to zero (less than 0.0045). The fitted parameters, including killing strength, effect window, and peak killing timing, quantitatively revealed significant heterogeneities in treatment responses across different PDTOs. Chemotherapy shows pronounced effectiveness in the early stage, while radiotherapy exhibits the effect later in the first week (around day 4), and a significantly stronger secondary response occurs one week after radiation (around day 8). Chemoradiotherapy combines the strengths of both modalities, producing pronounced effects in both response phases, with modeling results suggesting that the radiation-induced killing effect may play a dominant role in the combined interaction. CONCLUSIONS: Our modeling frameworks demonstrated high accuracy in modeling the heterogeneous therapeutic responses of PDTOs and provided insights into the dynamic killing effects and interplay between chemotherapy and radiotherapy. The modeling of therapeutic responses of PDTOs provides a valuable tool for optimizing treatment regimen and informing clinical trial design, thereby improving the efficacy of personalized medicine.
引用
- Yang C, Keepers Z, Shukla HD, et al. Tumor organoids modeling reveals timed responses and interplay of radiotherapy and chemotherapy in pancreatic cancer. Radiother Oncol. 2026. PMID: 41786221. doi:10.1016/j.radonc.2026.111470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。